GLP-1 receptor agonists, a class of medications prescribed to support metabolic health when clinically appropriate, have changed how many people consider their treatment options
Who Profits: Eli Lilly (LLY) FY2025 Revenue: $63.5B | GLP-1 Revenue (Mounjaro + Zepbound): $35-38B (estimated) | Operating Margin: 31% | CEO (David Ricks): $24.3M This issue's mechanism: Eli Lilly is winning the market share battle against Novo
Blood Pressure-Lowering Effects of GLP-1 Receptor Agonists Exenatide and Liraglutide: A Meta-Analysis of Clinical Trials
What Happens After Treatment Ends One of the most consequential findings in the GLP-1 literature has nothing to do with side effects during treatment it concerns what happens when treatment stops
Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials
Rotation and timing consistency Regardless of which site you prefer, injection site rotation is essential
